should be the target of all treatment strategies in psoriatic arthritis. All musculoskeletal and cutaneous manifestations of psoriatic disease need to be considered in treatment targets.

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.

UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...

Symptoms of psoriatic arthritis are similar to rheumatoid arthritis and include, pain, swelling and stiffness in one or more ...

Essentially, he was asking what makes RA different from the type of arthritis that you usually hear about: osteoarthritis.

By following these strategies, you can better manage morning stiffness and improve your comfort and mobility as you start ...